Ivelande Fleming, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 60 E Park St Apt 21b, East Orange, NJ 07017 Phone: 201-407-6877 |
Mrs. Derise Augustave, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 155 S Clinton St Bldg B, East Orange, NJ 07018 Phone: 914-268-5537 |
News Archive
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
Research from The Cancer Institute of New Jersey (CINJ) on biological pathways that govern progression and treatment responsiveness of HER2 positive breast cancer is being presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) being held in Orlando this week. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.
MR images taken of prostate cancer patients prior to treatment that show that the cancer has spread outside the prostate gland capsule help predict whether the cancer will return, according to a recent study conducted by radiologists at the University of California-San Francisco.
Mitt Romney is under fire for flip-flopping when he declared that the individual mandate is a tax, after a campaign adviser said it was not. In a front-page story, the New York Times wrote that Romney's statement "prompted renewed criticism that he was willing to adjust his views for political expediency." Bill Burton of the pro-Obama super PAC Priorities USA opined on what he called "Romney's ideological gymnastics."
PTC Therapeutics, Inc. today announced that final analyses of Phase 2b efficacy data suggest the investigational new drug ataluren slowed the loss of walking ability in patients with nonsense mutation dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular dystrophy (nmDBMD). These data were presented at the International Congress of the World Muscle Society in Kumamoto, Japan and will be the basis of interactions with the U.S. Food and Drug Administration (FDA) and national regulatory authorities in Europe in the fourth quarter of 2010.
› Verified 9 days ago